Conclusions: Analysis of left ventricular ejection fraction and first heart failure hospitalization in patients with T2DM treated with SGLT2 inhibitors reveals that empagliflozin is not only effective in glycemic control, weight management, and blood pressure reduction but also shows preventive potential against heart failure progression, even in patients without high cardiovascular risk. Here, SLC5A2 is linked to type 2 diabetes mellitus.